NEW YORK, Dec. 28, 2022 /PRNewswire/ -- Dominari Holdings
Inc. (Nasdaq: DOMH) ("Dominari" or the "Company") today provided an
update on the $2 million share
repurchase program (the "Share Repurchase Program") authorized by
the Company's Board of Directors on December
The Company reported that on December 27,
2022, the Company purchased 4,000 shares of common stock at
$3.1012 per share.
Anthony Hayes, CEO of Dominari,
stated, "The Company's stock is trading at levels we believe are
below its intrinsic value. To enhance shareholder value, we are
making purchases as part of our recently approved buyback
Additional shares may be repurchased from time to time in open
market transactions, or other means in accordance with Rule 10b5-1
of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), and Rule 10b -18 of the
Exchange Act. The timing, number of shares repurchased, and prices
paid for the stock under this program will depend on general
business and market conditions as well as corporate and regulatory
limitations, including blackout period restrictions.
About Dominari Holdings Inc.
Dominari Holdings Inc. (f/k/a AIkido Pharma Inc.) until recently
was focused primarily on the development of a diverse portfolio of
small-molecule anticancer and antiviral therapeutics and related
patent technology. In September 2022,
the Company agreed to acquire a registered broker-dealer and
transition its primary business operations to fintech and financial
services. Upon the final closing of this acquisition, the
Company's fintech and financial services business will be operated
through its subsidiary, Dominari Financial Inc. The Company
continues to develop its therapeutics and related patent
technology, as well as other ventures, through its subsidiary,
Aikido Labs, LLC.
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Brett Maas, Managing Partner
Phone: (646) 536-7331
Dominari Holdings Inc. (f/k/a AIkido Pharma
View original content to download
SOURCE Dominari Holdings Inc.